WG
BCLI

Winton Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Winton Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-798
Closed -$54K – 1371
2020
Q4 		$54K Sell
798
-5,699
-88% -$776K ﹤0.01% 1286
2020
Q3 		$1.65M Sell
6,497
-1,402
-18% -$287K 0.05% 622
2020
Q2 		$1.33M Buy
7,899
+2,768
+54% +$298K 0.03% 838
2020
Q1 		$357K Buy
5,131
+922
+22% +$72K 0.01% 1124
2019
Q4 		$270K Sell
4,209
-796
-16% -$46.2K ﹤0.01% 1383
2019
Q3 		$293K Buy
+5,005
New +$295K ﹤0.01% 1281

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Winton Group's BCLI Position: Q1 2021 in Review

Winton Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2021, closing a stake of 798 shares — an estimated $54K sold.

Winton Group first reported a position in BCLI in Q3 2019 and held it in 6 quarters. The position peaked at $1.65M in Q3 2020. 75 funds tracked by Wall St. Rank hold BCLI as of Q1 2021.

  • Winton Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2021 after selling out during the quarter.
  • Winton Group sold 798 BRAINSTORM CELL THERAPUTC shares in Q1 2021, an estimated $54K.
  • Winton Group first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2019 and held it in 6 quarters.
  • Winton Group's BRAINSTORM CELL THERAPUTC position peaked at $1.65M in Q3 2020.
  • 75 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2021.

Based on Winton Group's 13F filing for Q1 2021, filed 21 Jul 2021.